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Manzanares and colleagues, in their very comprehensive
systematic review with meta-analysis [1], conclude that
probiotics prove to be a very useful weapon to reduce
infections in critically ill patients, although strong rec-
ommendation in support of their use cannot be drawn
yet. Indeed, they correctly state that publication bias and
heterogeneity of the included studies could undermine
their conclusions [1]. Another relevant aspect of the
paper is the safety profile of probiotics, a well-known
matter of debate: no effect was observed upon length-of-
stay, diarrhea, and, most of all, mortality [1].
With regard to this crucial point, Fig. 3 in [1] describes
the overall effect on hospital mortality, with a risk ratio
equal to 0.98 (95% confidence interval 0.82–1.18); obvi-
ously the result is not significant but the direction of the
effect is in favour of probiotics. It is worth underlining
that their Fig. 3 reports a wrong datum about the mor-
tality in the trial by Besselink and colleagues [2], that is
24 out of 152 patients (as correctly reported in Table 2)
and not 14 out of 152 in the probiotics arm.
Reassessing the risk ratio with the meta-analytic soft-
ware ProMeta 3.0, the overall effect becomes 1.02 (95%
confidence interval 0.85–1.22), changing the direction of
the effect against the use of probiotics, although the result
is not significant. The weight of the results stemming from
the trial by Besselink and colleagues [2] is, for example,
clearly apparent in another systematic review with meta-
analysis published in Critical Care in 2014 [3].
In spite of their clinical use for a long time, the exact
role of probiotics in many therapeutic settings is still not
clear, and safety issues in special populations (pregnant
women, immunosuppressed, severe underlying diseases)
are the main matter of concern [4]. To this purpose,
providing the most precise information is fundamental
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